FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Top Story

Geron shares jump on GE stem cell pact

This morning the share price of Geron shot up 23 percent after the biotech company announced that it is teaming up with GE Healthcare to develop embryonic stem cell products that researchers can use in drug discovery work and tox screening. No terms were announced, but the new partners said that they would be using cell lines available through the National Institutes of Health's Human Pluripotent Stem Cell Registry. Article

Report

Lilly opens a portal to new drug collaborations

Eli Lilly is opening up a web portal that might just open up new collaborative initiatives with lab researchers around the world. Called the Lilly Phenotypic Drug Discovery Initiative, or PD2 (PD-squared), the portal will employ Lilly's disease-state assays to evaluate compounds synthesized at university and biotech labs around the globe.Article

Also Noted

Cancer Research

The New York Times makes the case that the $105 billion budgeted by the U.S. government for cancer research since the war on cancer was declared 38 years ago has become more of a jobs program than a scientific quest for a cure. New grants are often approved that will have little or no chance of advancing significant new therapies. And scientists are often all too willing to play it safe to gain a steady stream of research funds. Article

Researchers at The University of Texas M. D. Anderson Cancer Center have identified a protein that marks the tumor suppressor p53 for destruction, providing a potential new avenue for restoring p53 in cancer cells. Release

Read more >>